

Mymetics Corporation

Overview

May 2021

This document has been prepared by Mymetics Corporation ("Mymetics" or the "Company") for private circulation only. Mymetics is a public company listed on the OTC QB in the USA under MYMX whose European Executive Office is in Lausanne, Switzerland. This document should not be viewed as an offering circular, private placement memorandum or prospectus and does not constitute an offer, solicitation or invitation by or on behalf of Mymetics to any person to tender for, subscribe for, purchase or invest in any securities or any other investment. By accepting this document, the recipient agrees to keep this document confidential and not to reproduce it in whole or in part or distribute it outside of the firm to which it is provided without the written consent of Mymetics. At the request of Mymetics, the recipient must promptly return the document and all reproductions in whole or in part to Mymetics. The information and opinions contained in this document are for background purposes only and do not purport to be full or complete. It is not intended to provide the basis of any investment or other evaluation and is not and should not be construed as a recommendation or investment advice by Mymetics or any other person that any recipient of the document should make any investment. Mymetics has not independently verified the contents of the document. Accordingly, no representation, warranty or undertaking, express or implied, is made and no responsibility is accepted by Mymetics or any other party as to the accuracy or completeness in any respect of any information contained or statement made herein. All information in this document is subject to change without notice. The delivery of this document at any time does not imply that there has been no change since its date. This presentation includes forward-looking statements that relate to the Company's objectives, estimates and goals. Any statements that are not statements of historical fact should be considered forward-looking statements. The Company's business is subject to numerous risks and uncertainties, including the necessity to conduct further clinical trials and related studies, product testing and regulatory, approval, efficacy and safety. These and other risks and uncertainties could cause the company's actual results and developments to be materially different from those expressed or implied by any of these forward-looking Statements. Please refer to Mymetics' annual report as of December 31, 2020 on Form 10-K to the Securities and Exchange Commission for a full description of the Company's risks and operations. Any sales of the Company's securities pursuant to this confidential document are intended to be in compliance with Regulation S of the US Securities Act of 1933, as amended (the "Act"). It cannot therefore be made available to "US persons" within the meaning of rule 902(k) of the Act. No shares will be sold to US persons as defined above or to any person resident in the United States.

***Mymetics' vision is to become leading developer of
the new generation virosome based vaccines for
infectious and life disabling diseases***

Why Vaccines?

Prevention better than Treatment:

Lower Cost of Healthcare

Currently only 26 Infectious Diseases are Prevented by Vaccines: Many More to Address

Significant Unmet Needs Remain:

25% of worldwide annual deaths due to infectious disease (15M)¹
Major targets remain: RSV, CMV, HIV, HSV....SARS-CoV-2

Additionally - New Opportunities in Immunotherapy: Oncology and Allergies

Novel Vaccine Approaches Required

Vaccine Market to grow from \$37 Billion in 2019 to \$57 Billion in 2025 (CAGR 7.4%)²

Priority Target for Big Pharma: GSK, Merck, Sanofi, Pfizer, Seqirus-CSL (80%-85% of vaccine market)

Growth Driven Mainly by Innovation:

Blockbuster premium priced vaccines: Prevnar 13[®] ; Gardasil[®] ;
Rotateq[®] & Rotarix[®]; Shingrix[®];

¹ Fauci, et al Emerging Infectious Diseases 11 (4); 2005

² IMARC Dec 2020



Mymetics Corporation:	OTCQB MYMX – Venture Stage Market Place and current in SEC reporting
Location / resources:	HQ in Biopole Lausanne (CH) and R&D in Leiden (NL)
Core Competence:	World leading experts and IP in R&D and CMC for Virosome Technology Platform Integration and presentation of membrane proteins and antigens for innovative vaccine candidates against life disabling and infectious diseases.
Third Party Validation:	License, Collaboration and Funding Agreements with Pharma and Leading Foundations
Pipeline:	Clinical stage data: Intra-nasal Influenza, HIV and Malaria Pre-clinical data: SARS-CoV-2 (several collaborators) Cancer Immunotherapy (<i>several Partners</i>) Birch Pollen Allergy – two successful preclinical studies
Revenue Generating since Sep 2013:	cumulative more than > €15 million (collaborations and grant funding)

Important Events



- 2014 - 16: Gates Foundation \$1.8 million funded HIV vaccine study in NHPs at Texas Biomedical Research Inst.
- 2015 - 18: EU Horizon 2020 grant: €8.4 million - Achieved GMP thermostable / cold chain independent virosome vaccine in powder and capsule forms
- 2016 - 18: Research collaboration Project with Sanofi Pasteur (US) influenza virosomes
- 2016 - 18: Collaboration with NIH and LMIV for transmission blocking malaria vaccine
- 2018 - 20: EU funded development of multistage malaria virosome based vaccine
- 2018 - 20: Two projects with Anergis SA for Ultra Fast birch pollen Allergy Immunotherapy based on virosomes
Met all success criteria, beating Clinical Trial Phase 2 candidate in preclinical POC
- 2019 - to date: Started several collaboration projects with virosomes in the field of Cancer Immunotherapy
Generating strong induction of specific (CD8+) T-cells (Confidential Data)
- May 2019: NIH grant of USD 8.7 million for 5 year project: (i) rectal challenge study in non-human primates at University of Louisiana Lafayette and (ii) to prepare thermostable HIV vaccine candidate for clinical trials. (Results available by H2 2021)
- Apr. 2020 to date: Start of virosome-based Covid-19 vaccine development - with several collaborations
Baylor College of Medicine (RBD rprotein); Amsterdam Medical Center (S-protein); University Hospital Bern
Funding: European Community (Transvac2) and Innosuisse (Swiss Innovation Agency)

Virosomes


- Virosomes are virus-like particles consisting of virus envelopes
- Virosomes lack the genetic material of the native virus: **virosomes are non-infectious**
- Retain the **receptor-binding** and **membrane fusion** properties of the virus (membrane fusion elicits CD8+ Tcells)
- Lipid membrane allows **optimal presentation and folding of antigens**




virus



virosome vaccine



virosome as carrier platform
for vaccines










Starting Material:
Influenza virus as starting material
OR
Other enveloped virus (i.e. HSV, RSV, CMV, etc)

Advantages Virosome Platform

SAFETY:	No Genetic Material – Non-Infectious Safety in different populations: children, immune compromised, elderly Possible Administration: intra-muscular, intra-nasal, oral capsule or sublingual tablet
STABILITY:	Stable liquid or lyophilized virosome formulations Thermostable powder – cold chain independent virosome formulations possible
IMMUNOGENICITY:	Close to Nature: Reconstituted Natural Viral Membrane, Includes Natural Proteins of Virus Can include Antigens and Adjuvants in Membrane (All on one Particle) Optimal Presentation to Immune System (specific CD4+ and CD8+ T cell responses) Strong Induction of Systemic (blood) & Mucosal Immunity No interference of pre-existing influenza immunity – actually improves the response
BROADLY APPLICABLE:	For any Enveloped Virus and as Antigen Carrier System and as Antigen delivery carrier for Immunotherapy
SCALABLE & COST:	Large Scale and GMP enabled and low COGS
ALREADY PROVEN:	Epaxal [®] (Hep A) & Inflexal [®] (flu) – JNJ; Invivac [®] - Abbott (flu)

Mymetics Virosome Platform Pipeline Overview


	Discovery	Preclinical	Phase I	Phase II	Phase III	Partners	
Infectious Diseases	HIV	2021-22				     	
	Malaria						
	Influenza	On Hold					
	Chikungunya	On Hold					
	Covid-19	2020	2021-22				
Immuno Oncology	Different Indications	2019 - 21	2021-22			Several Not Disclosed Partners	
Allergy Immuno therapy	Birch pollen					two successful preclinical studies with 	

Mymetics SARS-CoV-2 Virosome-based Vaccine short term activities

Mymetics virosomes focusses on the following value points:

- broader efficacy & longer protection (including variants of concern)
 - avoid severe disease
 - intranasal administration - stop transmission and stop early infection events
 - modular and fungible production and low COGs
 - ease of storage and handling
- Produce and Test the different SARS2 virosome vaccines in preclinical animal models:
 - intranasal admin.
 - dose sparing
 - adjuvant selection
 - neutralizing antibodies
 - protection against challenge
 - absence of antibody enhanced disease
 - Preclinical Results during H2 2021
 - Select most promising candidate to go forward into clinical trials in 2022




SARS2 Virosome Vaccine



Academic Medical Center
University of Amsterdam



Some Pipeline Results: HIV virosome-based vaccine candidate


- 2007 - 2009
Preclinical NHP studies at ILAS – Beijing, China (Publication: Immunity, Feb. 2011)
 - ✓ 2 times i.m. and 2 times i.n. vaccinations
 - ✓ 100% protection with SHIV Clade B (NIAID) heterologous vaginal challenges
 - ✓ 40% protection with SHIV Clade C (R.Ruprecht) heterologous vaginal challenges
- 2009 - 2012
Phase I study – Leroux-Roels, Belgium (n=24) (Publication: PlosOne, Feb.2013)
 - ✓ Safe and very well tolerated (IM & IN)
 - ✓ High seroconversion rate within one injection
 - ✓ Mucosal IgGs & IgAs induced
 - ✓ Mucosal samples block HIV transcytosis
 - ✓ Human data confirming the macaque results
- 2014 - 2016
Gates Foundation \$1.8 million funded NHP HIV vaccine study with Texas Biomed. Research Inst

 - ✓ 78% to 87% protection against SHIV clade B (NIAID) during first 7 challenges
78.4% delay time-to-first viremia and 87% delay time-to-persistent systemic infection
- May 2019
NIH grant of \$ 8.67 million to prepare Mymetics HIV vaccine in liquid and powder forms for Clinical trials (5 year project).


 - ✓ Started May 1, 2019. First results expected in H2 2021.

Some Pipeline results: Virosomes for Cancer Immunotherapy

- Oct. 2018 - to date Started Collaboration Projects in Cancer Immunotherapy Field
- ✓ Virosomes - allow MHC Class I presentation
- ✓ Ability to incorporate cancer antigens/peptides and adj. in virosomes
- ✓ Strong specific CD8⁺ T cells in mice
- ✓ Started feasibility studies in CT26 and TC-I,
 - Inhibiting tumor growth (significant)
 - Increased survival (significant)

**Partners
Not Disclosed**

Detailed Data is Confidential




- Virosome vaccinated groups: significant CD8⁺ pentamer positive cells vs placebo.
- Ranging from 7% to 25% pentamer positive CD8⁺ T cells.

Some Pipeline results: Virosomes for Allergy Immunotherapy



➤ 2019

Preclinical Study Birch Pollen Immunotherapy - Collaboration Project with Anergis SA

- ✓ Met all success criteria - beating the AllerT - Anergis Phase 2 comparator.
- no IgE induction - strong immunogenicity - high Th1 response



Box and whiskers; Tukey
Mann-Whitney; unpaired; nonparametric; two-tailed



Mean ± standard deviation
Dunn's multiple comparisons test

➤ 2020

Study by Stallergenes Greer SA and Anergis SA

Virosomes coupled to Bet v 1 COPs triggered a boosted Th1 immunity and favorable safety profile. Virosomes were able to fully reverse asthma symptoms and lung inflammation in a sublingual therapeutic model of birch pollen allergy ⁽¹⁾

(1) Journal Clinical & Experimental Allergy, January 2021: Bet v 1 contiguous overlapping peptides anchored to virosomes with TLR4 agonist enhance immunotherapy efficacy in mice.

Some Pipeline Results: Malaria virosome-based vaccine candidate

- 2008 - 2010 Phase Ib study in children in Tanzania (n=30) (Publication: PlosOne, 6: e22273, 2011)
Virosome vaccine with AMA-1 and CSP1 antigens, 2 times i.m. injection (Blood & Liver stage)



- ✓ Safe and very well tolerated
- ✓ High seroconversion rate within one injection
- ✓ Attack rate (single event – KM curves)
 - Day 30 - 90: 28% vs 73% (comparator)
 - Day 120 - 365: 50% vs 80% (comparator)
- ✓ Attack rate (multiple events): 50% reduction (p=0.02)
- ✓ Similar to GSK RTS,S BUT without adjuvant

- Nov. 2014 - Dec. 2018 PATH-MVI funded study for transmission blocking malaria virosome vaccine (Pfs230)



- ✓ High Ab titers and 95% to 100% transmission blocking of parasites

- Jun. 2018 - 2019 Improvement of malaria vaccine by adding two new antigens (RH5 and CyRPA) and adjuvant



- ✓ Successful incorporation of 4 antigens and adjuvant
- ✓ Animal studies (Abs and Growth Inhibition)

Financial Summary

- OTC QB: MYMX – current in SEC reporting and filings but not leveraged public listing until now
- 303 million shares outstanding, public float approximately 25%
- Capital Raised last 8 years: \$25 million in equity; \$40 million in convertible debt through private funding
- 55% of Company held by executives / board members
- Since September 2013 revenue generating and low cash burn

- Unique vaccine technology, know-how and IP: virosome as antigen carrier
- World leading virosome and membrane protein expertise and know-how
- Attractive and diverse pipeline with excellent results to date
- Multiple collaboration agreements with Pharma and Biotech companies
- Obtained non-dilutive funding from Gates Foundation, PATH MVI, NIH and EU Horizon 2020 for HIV and malaria vaccine development
- Revenue generating since September 2013
- Strong Management Team and Scientific Advisors